Invention Grant
US09540439B2 Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
有权
基于通过神经丝氨酸-1：信号素轴调节T细胞稳定性和功能的治疗
- Patent Title: Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
- Patent Title (中): 基于通过神经丝氨酸-1：信号素轴调节T细胞稳定性和功能的治疗
-
Application No.: US14434129Application Date: 2013-10-08
-
Publication No.: US09540439B2Publication Date: 2017-01-10
- Inventor: Dario A. A. Vignali , Seng-ryong Woo , Greg M. Delgoffe
- Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
- Applicant Address: US TN Memphis
- Assignee: St. Jude Children's Research Hospital
- Current Assignee: St. Jude Children's Research Hospital
- Current Assignee Address: US TN Memphis
- Agency: Fenwick & West LLP
- International Application: PCT/US2013/063934 WO 20131008
- International Announcement: WO2014/058915 WO 20140417
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K38/17 ; A61K31/713 ; C12N5/0783 ; C12N15/113 ; A61K39/00
Abstract:
The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory T cell (Treg)-restricted neuropilin-1 (Nrp 1) interacts with the cell surface ligand semaphorin-4a (Sema4a) (e.g., on conventional T cells (Tconv), conventional dendritic cells (cDCs), and/or plasmacytoid dendritic cells (pDCs)) to potentiate reg function and enhance their survival at inflammatory sites.
Public/Granted literature
Information query
